title: Stimulation of cells derived from nifedipine-induced gingival overgrowth with Porphyromonas gingivalis, lipopolysaccharide, and interleukin-1beta.
abstract: The purpose of this study was to clarify the main contributory factor of nifedipine-induced gingival overgrowth either by Porphyromonas gingivalis lipopolysaccharide (Pg-LPS) or interleukin-1beta (IL-1beta). Human gingival fibroblasts from healthy tissues and nifedipine-induced gingival overgrowth tissues were stimulated with nifedipine, IL-1beta, Escherichia coli lipopolysaccharide (Ec-LPS), and Pg-LPS, and the gene expressions were analyzed by RT-PCR. Analysis of the data showed no strong evidence of a synergistic effect of nifedipine and Pg-LPS on IL-6, connective tissue growth factor (CTGF), and type 1 collagen gene expression of either healthy cells or nifedipine-induced gingival overgrowth cells. Among the three stimulants--IL-1beta, Pg-LPS, and Ec-LPS--androgen receptor and IL-6 gene expressions in both the healthy and nifedipine-induced gingival overgrowth groups were strongly up-regulated by the presence of IL-1beta only. Furthermore, the responses to IL-1beta in the nifedipine-induced gingival overgrowth group were stronger than those of the healthy group. It can be concluded that IL-1beta is an important mediator responsible for the higher IL-6 and androgen receptor expression of nifedipine-induced gingival overgrowth cells.
authors.affiliation: Periodontal Clinic of the Dental Department, Taipei Medical University Hospital, Taipei, Taiwan.
authors.forename: H-K
authors.initials: HK
authors.lastname: Lu
authors.forename: H-P
authors.initials: HP
authors.lastname: Chou
authors.forename: C-L
authors.initials: CL
authors.lastname: Li
authors.forename: M-Y
authors.initials: MY
authors.lastname: Wang
authors.forename: L-F
authors.initials: LF
authors.lastname: Wang
mesh_terms: D000368:Aged; D002121:Calcium Channel Blockers / Q000009:adverse effects; D016022:Case-Control Studies; D024042:Collagen Type I / Q000096:biosynthesis; D055513:Connective Tissue Growth Factor; D004357:Drug Synergism; D004926:Escherichia coli; D019214:Gingival Overgrowth / Q000139:chemically induced / Q000378:metabolism*; D006801:Humans; D017874:Immediate-Early Proteins / Q000096:biosynthesis; D036341:Intercellular Signaling Peptides and Proteins / Q000096:biosynthesis; D053583:Interleukin-1beta / Q000494:pharmacology / Q000502:physiology*; D015850:Interleukin-6 / Q000096:biosynthesis; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000009:adverse effects; D016966:Porphyromonas gingivalis; D011944:Receptors, Androgen / Q000096:biosynthesis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D018709:Statistics, Nonparametric
chemical_list: C526317:CCN2 protein, human; D002121:Calcium Channel Blockers; D024042:Collagen Type I; D017874:Immediate-Early Proteins; D036341:Intercellular Signaling Peptides and Proteins; D053583:Interleukin-1beta; D015850:Interleukin-6; D008070:Lipopolysaccharides; D011944:Receptors, Androgen; D055513:Connective Tissue Growth Factor; D009543:Nifedipine